Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions
Effects of other drugs on Psilocybin
10 evidence topics · 9 sources
Regulatory summary of interactions with antidepressants and lithium
SSRIs and SNRIs: attenuation of psilocybin effects in survey reports
“In reports (n = 611) of taking mushrooms with an antidepressant, probabilities [95% CI] of weaker than expected drug effects were 0.47 [0.41-0.54] (selective serotonergic reuptake inhibitors, SSRIs), 0.55 [0.44-0.67] (serotonin norepinephrine reuptake inhibitors, SNRIs) and 0.29 [0.2-0.39] (bupropion).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SSRI/SNRIs appear to weaken psilocybin drug effects relative to a non-serotonergic antidepressant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This dampening effect may last as long as 3 months following antidepressant discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Escitalopram pretreatment before psilocybin 25 mg in healthy participants
“Pretreatment consisted of 10 mg escitalopram daily for 7 days, followed by 20 mg daily for 7 days, including the day of psilocybin administration, or 14 days of placebo pretreatment before psilocybin administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Escitalopram pretreatment had no relevant effect on positive mood effects of psilocybin but significantly reduced bad drug effects, anxiety, adverse cardiovascular effects, and other adverse effects of psilocybin compared with placebo pretreatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Escitalopram did not alter the pharmacokinetics of psilocin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further studies are needed with a longer antidepressant pretreatment time and patients with psychiatric disorders to further define interactions between antidepressants and psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ongoing SSRI treatment with COMP360 25 mg in treatment-resistant depression
“There were meaningful improvements in depression severity from Baseline to Week 3, indicating that ongoing SSRI treatment did not inhibit the therapeutic potential of psilocybin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Taken together, these findings suggest that the pharmacological interactions necessary for psilocybin to take effect are not meaningfully compromised by SSRIs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recent antidepressant discontinuation before COMP360 in the phase 2b trial
“Antidepressant drug discontinuation was not related to worsening of depression severity before Baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin treatment efficacy and the subjective psychedelic experience did not appear to be compromised by antidepressant drug discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chronic antidepressant exposure and 5-HT2A receptors in preclinical studies
“More convincingly, chronic administration of antidepressant drugs, including a selective serotonin reuptake inhibitor (SSRI), reduced the head-twitch response, a stereotypic behavior exhibited by rodents in response to 5-HT2A agonizts and also downregulated 5-HT2A receptors, which are considered essential for the subjective psychedelic effects of psilocybin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lithium and seizures
“They found that 2 of the 6 reports of lithium plus psilocybin resulted in seizures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the 10 reports of lamotrigine plus psilocybin resulted in seizures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monoamine oxidase inhibitors
“Inhibition of psilocin inactivation by MAO could potentially augment the metabolic pathway catalyzed by CYP2D6, thereby altering the pharmacodynamics of psilocybin therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, glucuronidation of psilocin would likely continue to be the predominant metabolic pathway, rendering MAO inhibition potentially less important.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
UGT1A9 and UGT1A10 inhibitors and estradiol
“Diclofenac and probenecid are examples of UGT1A9/10 inhibitors that may hypothetically alter psilocybin metabolism if co-ingested; however, there is no evidence to confirm this hypothesis beyond shared metabolism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are few pharmacologic agents that influence UGT1A9 and UGT1A10” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This suggests that hormone replacement therapy, oral contraceptives, and cyclical hormonal changes may affect the metabolism of psilocybin, highlighting the need for more inclusive research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antipsychotics and 5-HT2A receptor antagonists
“Haloperidol pretreatment reduced psilocybin effects on the Oceanic boundlessness, measures of derealisation and depersonalisation phenomena but increased anxiety without any effects on visual hallucinations or delayed response tasks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Risperidone pretreatment attenuated the effects of psilocybin in a dose-dependent manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ketanserin pretreatment blocked psilocybin effects in a dose-dependent manner on the delayed response task and Altered State of Consciousness Rating scale.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Except for a few case reports, no serious adverse drug events were described in the included studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote